Third Rock Ventures III, L.P.'s Net Worth

$768 Million

Who is Third Rock Ventures III, L.P.?

Third Rock Ventures III, L.P. has an estimated net worth of $768 Million. This is based on reported shares across multiple companies, which include Fulcrum Therapeutics, Inc., Revolution Medicines, Inc., PLIANT THERAPEUTICS, INC., Editas Medicine, Inc., Jounce Therapeutics, Inc., Voyager Therapeutics, Inc., Nurix Therapeutics, Inc., Global Blood Therapeutics, Inc., Relay Therapeutics, Inc., MyoKardia Inc, Neon Therapeutics, Inc., and Decibel Therapeutics, Inc..

SEC CIK

Third Rock Ventures III, L.P.'s CIK is 0001569705

Past Insider Trading and Trends

2020 was Third Rock Ventures III, L.P.'s most active year for acquiring shares with 11 total transactions. Third Rock Ventures III, L.P.'s most active month to acquire stocks was the month of June. 2021 was Third Rock Ventures III, L.P.'s most active year for disposing of shares, totalling 18 transactions. Third Rock Ventures III, L.P.'s most active month to dispose stocks was the month of December. 2019 saw Third Rock Ventures III, L.P. paying a total of $1,300,000.00 for 5,676,488 shares, this is the most they've acquired in one year. In 2021 Third Rock Ventures III, L.P. cashed out on 13,022,394 shares for a total of $243,054,711.61, their largest year based on trade value.